{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:12:46Z","timestamp":1788369166797,"version":"build-2803163510"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nonhuman primate research has been critical for the advancement of human immunodeficiency virus (HIV) prevention, including the development of preexposure prophylaxis. Many studies have been conducted by or in partnership with the Centers for Disease Control and Prevention (CDC) and\/or the National Institutes of Health. In November 2025, scientists at the CDC were notified that studies involving animal research and specifically nonhuman primate research were being eliminated. These and other efforts to eliminate nonhuman primate research will have serious consequences in the field of HIV prevention and will hamper future efforts to develop and evaluate HIV prevention approaches including preexposure prophylaxis.<\/jats:p>","DOI":"10.1093\/infdis\/jiag089","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:40:30Z","timestamp":1770468030000},"page":"175-177","source":"Crossref","is-referenced-by-count":1,"title":["The Contribution and Importance of Animal Research to HIV Prevention in the United States"],"prefix":"10.1093","volume":"234","author":[{"given":"Philip A","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Medicine, Brown University , Providence, Rhode Island ,","place":["USA"]},{"name":"Rhode Island Public Health Institute , Providence, Rhode Island ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026090212172950400_jiag089-B1","author":"Grimm"},{"key":"2026090212172950400_jiag089-B2","doi-asserted-by":"publisher","author":"Chan","DOI":"10.1377\/forefront.20251104.875324\/full\/"},{"key":"2026090212172950400_jiag089-B3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2025.12688","article-title":"Grant terminations in the US threaten HIV research and future progress","volume":"334","author":"Chan","year":"2025","journal-title":"JAMA"},{"key":"2026090212172950400_jiag089-B4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.36.11.2381","article-title":"Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection","volume":"36","author":"Van Rompay","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090212172950400_jiag089-B5","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"2026090212172950400_jiag089-B6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1086\/507306","article-title":"Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges","volume":"194","author":"Subbarao","year":"2006","journal-title":"J Infect Dis"},{"key":"2026090212172950400_jiag089-B7","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garc\u00eda-Lerma","year":"2008","journal-title":"PLoS Med"},{"key":"2026090212172950400_jiag089-B8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews","year":"2014","journal-title":"Science"},{"key":"2026090212172950400_jiag089-B9","doi-asserted-by":"crossref","first-page":"270ra5","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026090212172950400_jiag089-B10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/infdis\/jiw312","article-title":"Chemoprophylaxis with oral emtricitabine and tenofovir alafenamide combination protects macaques from rectal simian\/human immunodeficiency virus infection","volume":"214","author":"Massud","year":"2016","journal-title":"J Infect Dis"},{"key":"2026090212172950400_jiag089-B11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/infdis\/jiaa095","article-title":"Long-acting cabotegravir protects macaques against repeated penile simian-human immunodeficiency virus exposures","volume":"222","author":"Dobard","year":"2020","journal-title":"J Infect Dis"},{"key":"2026090212172950400_jiag089-B12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41586-021-04279-4","article-title":"Long-acting capsid inhibitor protects macaques from repeat SHIV challenges","volume":"601","author":"Vidal","year":"2022","journal-title":"Nature"},{"key":"2026090212172950400_jiag089-B13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41467-023-36330-5","article-title":"Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection","volume":"14","author":"Young","year":"2023","journal-title":"Nat Commun"},{"key":"2026090212172950400_jiag089-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7401a1","article-title":"Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV-CDC recommendations, United States, 2025","volume":"74","author":"Tanner","year":"2025","journal-title":"MMWR Recomm Rep"},{"key":"2026090212172950400_jiag089-B15","first-page":"255","article-title":"Nonhuman primate models in AIDS research","volume":"8","author":"Evans","year":"2013","journal-title":"Curr Opin HIV AIDS"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag089\/66855739\/jiag089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/175\/66855739\/jiag089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/175\/66855739\/jiag089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:17:43Z","timestamp":1788365863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/2\/175\/8473477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag089","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,2,17]]}}}